Giuli Dott.ssa Valentina
Pubblicazioni su PubMed
Myocardial involvement in children with post-COVID multisystem inflammatory syndrome: a cardiovascular magnetic resonance based multicenter international study-the CARDOVID registry.
J Cardiovasc Magn Reson2021 12;23(1):140. doi: 10.1186/s12968-021-00841-1.
Aeschlimann Florence A, Misra Nilanjana, Hussein Tarique, Panaioli Elena, Soslow Jonathan H, Crum Kimberly, Steele Jeremy M, Huber Steffen, Marcora Simona, Brambilla Paolo, Jain Supriya, Navallas Maria, Giuli Valentina, Rücker Beate, Angst Felix, Patel Mehul D, Azarine Arshid, Caro-Domínguez Pablo, Cavaliere Annachiara, Di Salvo Giovanni, Ferroni Francesca, Agnoletti Gabriella, Bonnemains Laurent, Martins Duarte, Boddaert Nathalie, Wong James, Pushparajah Kuberan, Raimondi Francesca
Recent evidence shows an association between coronavirus disease 2019 (COVID-19) infection and a severe inflammatory syndrome in children. Cardiovascular magnetic resonance (CMR) data about myocardial injury in children are limited to small cohorts. The aim of this multicenter, international registry is to describe clinical and cardiac characteristics of multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 using CMR so as to better understand the real extent of myocardial damage in this vulnerable cohort.
METHODS AND RESULTS:
Hundred-eleven patients meeting the World Health Organization criteria for MIS-C associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), having clinical cardiac involvement and having received CMR imaging scan were included from 17 centers. Median age at disease onset was 10.0 years (IQR 7.0-13.8). The majority of children had COVID-19 serology positive (98%) with 27% of children still having both, positive serology and polymerase chain reaction (PCR). CMR was performed at a median of 28 days (19-47) after onset of symptoms. Twenty out of 111 (18%) patients had CMR criteria for acute myocarditis (as defined by the Lake Louise Criteria) with 18/20 showing subepicardial late gadolinium enhancement (LGE). CMR myocarditis was significantly associated with New York Heart Association class IV (p?=?0.005, OR 6.56 (95%-CI 1.87-23.00)) and the need for mechanical support (p?=?0.039, OR 4.98 (95%-CI 1.18-21.02)). At discharge, 11/111 (10%) patients still had left ventricular systolic dysfunction.
No CMR evidence of myocardial damage was found in most of our MIS-C cohort. Nevertheless, acute myocarditis is a possible manifestation of MIS-C associated with SARS-CoV-2 with CMR evidence of myocardial necrosis in 18% of our cohort. CMR may be an important diagnostic tool to identify a subset of patients at risk for cardiac sequelae and more prone to myocardial damage.
CLINICAL TRIAL REGISTRATION:
The study has been registered on ClinicalTrials.gov, Identifier NCT04455347, registered on 01/07/2020, retrospectively registered.
© 2021. The Author(s).
Guarda su PubMed
Validation of the Somnotouch-NIBP noninvasive continuous blood pressure monitor according to the European Society of Hypertension International Protocol revision 2010.
Blood Press Monit2015 Oct;20(5):291-4. doi: 10.1097/MBP.0000000000000124.
Bilo Grzegorz, Zorzi Cristina, Ochoa Munera Juan E, Torlasco Camilla, Giuli Valentina, Parati Gianfranco
The present study aimed to evaluate the accuracy of the Somnotouch-NIBP noninvasive continuous blood pressure monitor according to the European Society of Hypertension International Protocol revision 2010.
MATERIALS AND METHODS:
Systolic and diastolic blood pressures were sequentially measured in 33 adults (11 women, mean age 63.5±11.9 years) using a mercury sphygmomanometer (two observers) and the Somnotouch-NIBP device (one supervisor). A total of 99 pairs of comparisons were obtained from 33 participants for judgments in two parts with three grading phases.
All the validation requirements were fulfilled. The Somnotouch-NIBP device fulfilled the requirements of the part 1 of the validation study. The number of absolute differences between device and observers within 5, 10, and 15?mmHg was 75/99, 90/99, and 96/99, respectively, for systolic blood pressure and 90/99, 99/99, and 99/99, respectively, for diastolic blood pressure. The device also fulfilled the criteria in part 2 of the validation study. Twenty-seven and 31 participants had at least two of the three device-observers differences less than or equal to 5?mmHg for systolic and diastolic blood pressure, respectively. All three device-observer differences were greater than 5?mmHg in two participants for systolic and in one participant for diastolic blood pressure.
The Somnotouch-NIBP noninvasive continuous blood pressure monitor has passed the requirements of the International Protocol revision 2010, and hence can be recommended for blood pressure monitoring in adults, at least under conditions corresponding to those investigated in our study.
Guarda su PubMed
Diastolic dysfunction in controlled hypertensive patients with mild-moderate obstructive sleep apnea.
Int J Cardiol2015 ;187():686-92. doi: 10.1016/j.ijcard.2015.02.037.
Lisi Elisabetta, Faini Andrea, Bilo Grzegorz, Lonati Laura Maria, Revera Miriam, Salerno Sabrina, Giuli Valentina, Lombardi Carolina, Parati Gianfranco
Hypertension and severe obstructive sleep apnea (OSA) may independently contribute to left ventricular diastolic dysfunction. However, scanty data is available on this issue in hypertensives with mild-moderate OSA.
METHODS AND RESULTS:
We performed polysomnography, echocardiography and 24h ambulatory blood pressure monitoring in 115 treated essential hypertensives with suspicion of OSA. After exclusion of severe/treated OSA and/or cardiovascular disease patients, mild-moderate OSA (5 ? apnoea/hypopnoea index
In controlled hypertensives mild-moderate OSA may be associated with early diastolic dysfunction, independently from age, gender and mean blood pressure and in the absence of concentric left ventricular hypertrophy. Moreover nocturnal hypoxia may be a key factor in determining early diastolic dysfunction, under the synergic effects of hypertension and mild-moderate OSA.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Guarda su PubMed